Results 181 to 190 of about 786,540 (316)

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Plant growth substances proceedings of the ... Internat. Conference on Plant Growth Substances . .

, 1982
International Conference on Plant Growth Substances
core  

A new use of Agrobacterium plant growth regulator genes for plant bioengineering. [PDF]

Front Plant Sci
Heck M, Pitino M, Coradetti S, DeBlasio SL, Cooper WR, Shrum L, Harper D, Stallone M, Scott A, Cook R, Rhodes B, Sullivan S, Schechter E, Cochrane E, Larson N, Locatelli G, Hodge J, Grando MF, Wang L, Ariyarante M, Tibebu R, Stange R, Howe KJ, Makar A, Stuehler D, Thompson L, Shende K, Hentz M, Gaza N, Weeks-Purdy C, Chang B, Nikoomanzar A, Bennett L, Demirden N, Hunter W, Thomson J, Ritenour MA, Rossi L, Cano LM, Adair RC, Stover E, McKenzie CL, Niedz R, Shatters RG.   +43 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Synergistic effects of plant growth regulators, riboflavin, and iron nanoparticles on secondary metabolites in micropropagated Ceratonia siliqua L. [PDF]

Sci Rep
Taha LS, Youssef NM, Ibrahim EA, El-Sayed IM.   +3 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Plant Growth Regulator Residues in Edible Mushrooms: Are They Hazardous? [PDF]

Foods
Yao Q, Su D, Lin X, Xu H, Zheng Y, Xiao Y.   +5 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Artificial soil (ArtSoil): Recreating soil conditions in synthetic plant growth media. [PDF]

Plant J
Kaplunova V, Alioui H, Griguschies T, Müller L, Joisten-Rosenthal V, Lautwein T, Metzger S, Durán P, Loo E.   +8 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source